Guardian Pharmacy Services Files S-1/A Amendment
Ticker: GRDN · Form: S-1/A · Filed: Sep 16, 2024 · CIK: 1802255
Sentiment: neutral
Topics: ipo, pharmacy, sec-filing
TL;DR
Guardian Pharmacy Services filed an S-1/A, prepping for IPO. Watch this space.
AI Summary
Guardian Pharmacy Services, Inc. filed an S-1/A amendment on September 16, 2024, for its initial public offering. The company, incorporated in Delaware, is based in Atlanta, Georgia, and operates in the retail drug store sector. This filing is an amendment to a previous registration statement (No. 333-274847) and provides updated information for potential investors.
Why It Matters
This S-1/A filing indicates Guardian Pharmacy Services is moving forward with its plans to become a publicly traded company, which could impact its growth, operations, and the competitive landscape of the pharmacy sector.
Risk Assessment
Risk Level: medium — As a company pursuing an IPO, Guardian Pharmacy Services faces inherent market risks, regulatory hurdles, and the challenges of operating as a public entity.
Key Numbers
- 333-274847 — SEC File Number (Identifies the registration statement for this offering.)
- 5912 — SIC Code (Indicates the company operates in the Retail - Drug Stores and Proprietary Stores industry.)
Key Players & Entities
- Guardian Pharmacy Services, Inc. (company) — Registrant
- 300 Galleria Parkway SE Suite 800 Atlanta, Georgia 30339 (location) — Principal executive offices
- Fred P. Burke (person) — President and Chief Executive Officer
- 333-274847 (registration_number) — SEC File Number
- 20240916 (date) — Filing Date
FAQ
What is the purpose of this S-1/A filing?
This S-1/A filing is an amendment to the initial Form S-1 registration statement, providing updated information for Guardian Pharmacy Services, Inc. as it prepares for an initial public offering (IPO).
Who is the principal executive officer of Guardian Pharmacy Services, Inc.?
Fred P. Burke is the President and Chief Executive Officer of Guardian Pharmacy Services, Inc.
Where is Guardian Pharmacy Services, Inc. headquartered?
Guardian Pharmacy Services, Inc. is headquartered at 300 Galleria Parkway SE, Suite 800, Atlanta, Georgia 30339.
What is the company's Standard Industrial Classification (SIC) code?
The company's SIC code is 5912, which corresponds to Retail - Drug Stores and Proprietary Stores.
When was this amendment filed with the SEC?
This amendment (S-1/A) was filed with the SEC on September 16, 2024.
Filing Stats: 4,458 words · 18 min read · ~15 pages · Grade level 15.4 · Accepted 2024-09-16 08:22:42
Key Financial Figures
- $14.00 — the public offering price to be between $14.00 and $16.00 per share. Currently, no pub
- $16.00 — offering price to be between $14.00 and $16.00 per share. Currently, no public market
- $68 million — ave built this business with a total of $68 million of cash invested as equity capital and
- $1.1 b — evenue through June 30, 2024 surpassing $1.1 billion, we have modest debt and we are c
- $1.046 b — or the year ended December 31, 2023 was $1.046 billion, compared to $908.9 million for t
- $908.9 million — 1, 2023 was $1.046 billion, compared to $908.9 million for the year ended December 31, 2022, o
- $37.7 m — or the year ended December 31, 2023 was $37.7 million, compared to $49.7 million for th
- $49.7 million — 31, 2023 was $37.7 million, compared to $49.7 million for the year ended December 31, 2022, a
- $76.2 m — or the year ended December 31, 2023 was $76.2 million, compared to $65.7 million for th
- $65.7 million — 31, 2023 was $76.2 million, compared to $65.7 million for the year ended December 31, 2022. I
- $575.4 m — track record of growth, with revenue of $575.4 million, net income of $22.9 million, Adj
- $22.9 m — evenue of $575.4 million, net income of $22.9 million, Adjusted EBITDA of $41.9 million
- $41.9 million — me of $22.9 million, Adjusted EBITDA of $41.9 million and residents served of approximately 1
- $52.0 million — 4, we have modest leverage with debt of $52.0 million. We have long believed in promoting emp
- $24.8 billion — market revenues would be approximately $24.8 billion in 2024. The U.S. institutional pharmac
Filing Documents
- d856029ds1a.htm (S-1/A) — 1714KB
- d856029dex11.htm (EX-1.1) — 225KB
- d856029dex21.htm (EX-2.1) — 12KB
- d856029dex33.htm (EX-3.3) — 41KB
- d856029dex34.htm (EX-3.4) — 119KB
- d856029dex41.htm (EX-4.1) — 78KB
- d856029dex51.htm (EX-5.1) — 7KB
- d856029dex101.htm (EX-10.1) — 92KB
- d856029dex102.htm (EX-10.2) — 91KB
- d856029dex103.htm (EX-10.3) — 92KB
- d856029dex105.htm (EX-10.5) — 104KB
- d856029dex231.htm (EX-23.1) — 1KB
- d856029dex232.htm (EX-23.2) — 1KB
- d856029dexfilingfees.htm (EX-FILING FEES) — 43KB
- g856029g01s11.jpg (GRAPHIC) — 128KB
- g856029g04k04.jpg (GRAPHIC) — 159KB
- g856029g05t69.jpg (GRAPHIC) — 139KB
- g856029g08a09.jpg (GRAPHIC) — 198KB
- g856029g11i66.jpg (GRAPHIC) — 77KB
- g856029g11l83.jpg (GRAPHIC) — 975KB
- g856029g18c77.jpg (GRAPHIC) — 174KB
- g856029g50k65.jpg (GRAPHIC) — 111KB
- g856029g50w50.jpg (GRAPHIC) — 217KB
- g856029g60a01.jpg (GRAPHIC) — 115KB
- g856029g64h76.jpg (GRAPHIC) — 186KB
- g856029g70l27.jpg (GRAPHIC) — 106KB
- g856029g76a04.jpg (GRAPHIC) — 79KB
- g856029g79n59.jpg (GRAPHIC) — 105KB
- g856029g85l86.jpg (GRAPHIC) — 2KB
- g856029g85p03.jpg (GRAPHIC) — 88KB
- g856029g95i98.jpg (GRAPHIC) — 93KB
- 0001193125-24-219239.txt ( ) — 6641KB
Risk Factors
Risk Factors 25 Special Note Regarding Forward-Looking Statements 46 Corporate Reorganization 48
Use of Proceeds
Use of Proceeds 51 Dividend Policy 52 Capitalization 53
Managements Discussion and Analysis of Financial Condition and Results
Managements Discussion and Analysis of Financial Condition and Results of Operations 58
Business
Business 72 Management 105
Executive Compensation
Executive Compensation 116 Director Compensation 125 Certain Relationships and Related Party Transactions 126
Security Ownership of Certain Beneficial Owners and
Security Ownership of Certain Beneficial Owners and Management 128
Description of Capital Stock
Description of Capital Stock 130 Shares Eligible for Future Sale 137 Material U.S. Federal Income Tax Considerations for Non-U.S. Holders 139
Underwriting
Underwriting 144 Legal Matters 152 Experts 152 Where You Can Find More Information 152 Index to Consolidated Financial Statements F-1 You should rely only on the information contained in this prospectus or contained in any free writing prospectus that we have filed with the Securities and Exchange Commission (the SEC). Neither we nor the underwriters have authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by us or on our behalf or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the Class A common stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is accurate only as of its date regardless of the time of delivery of this prospectus or of any sale of our Class A common stock. Our business, financial condition, results of operations and prospects may have changed since that date. We are offering to sell, and seeking offers to buy, our Class A common stock only in jurisdictions where such offers and sales are permitted. For investors outside the United States, neither we nor the underwriters have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside the United States who come into possession of this prospectus and any free writing prospectus related to this offering are required to inform themselves about, and to observe any restrictions related to, the offering of the shares of our Class A common stock and the distribution of this prospectus and any such free writing prospectus outside of the United States. i Tabl